grant
Nanotechnology Core C
Organization UNIVERSITY OF PITTSBURGH AT PITTSBURGHLocation PITTSBURGH, UNITED STATESPosted 3 Jul 2025Deadline 31 May 2030
NIHUS FederalResearch GrantFY2025AntibodiesAreaB cell differentiation factorB cell stimulating factor 2B-Cell Differentiation FactorB-Cell Differentiation Factor-2B-Cell Stimulatory Factor-2BCDFBSF-2BSF2BindingBody TissuesCancersCardiovascularCardiovascular Body SystemCardiovascular Organ SystemCardiovascular systemCell BodyCell FunctionCell PhysiologyCell ProcessCellsCellular FunctionCellular PhysiologyCellular ProcessCharacteristicsChargeChronicClinicalClinical Treatment MoabClinical TrialsDataDendritic CellsDevelopmentDiseaseDisorderDoseDrug DeliveryDrug Delivery SystemsDrug KineticsDrug TargetingDrugsEncapsulatedFK506 Binding Protein 12-Rapamycin Associated Protein 1FKBP12 Rapamycin Complex Associated Protein 1FRAP1FRAP1 geneFRAP2GenerationsGoalsGraft SurvivalGrafting ProcedureHPGFHeart VascularHepatocyte-Stimulating FactorHybridoma Growth FactorIFN-beta 2IFNB2IL-6IL6 ProteinImmuneImmunesImmunomodulationImmunosuppressantsImmunosuppressionImmunosuppression EffectImmunosuppressive AgentsImmunosuppressive EffectImmunosuppressive drugImmunosuppressive treatmentImmunotherapeutic agentIn SituInfusionInfusion proceduresInjectionsInterleukin-6Kidney GraftingKidney TransplantationKidney TransplantsKineticsLabelMGI-2Malignant NeoplasmsMalignant TumorMechanistic Target of RapamycinMedicalMedicationMedicineMetabolic syndromeMethodsModalityModificationMolecular InteractionMonoclonal AntibodiesMorbidityMorbidity - disease rateMyeloid Differentiation-Inducing ProteinNanodeliveryNanotechnologyOrganOrgan TransplantationOrgan TransplantsOutcomePathogenesisPatientsPeptidesPerfusionPharmaceutical PreparationsPharmacokineticsPhenotypePhysiologic pulsePlasmacytoma Growth FactorPulseRAFT1RapamuneRapamycinReceptor ProteinRegimenRenal GraftingRenal TransplantationRenal TransplantsReportingResearchRhesusRiskScheduleShapesSirolimusSiteStandardizationSubcellular ProcessSurfaceTechnologyTestingTherapeuticTimeTissue GraftsTissue imagingTissuesToxic effectToxicitiesTransplantationTransplantation ToleranceVeiled CellsWorkcancer transplantationcell typecirculatory systemclinical practicecontrolled releasedesigndesigningdevelopmentaldrug withdrawaldrug/agentexperimentexperimental researchexperimental studyexperimentsfluorophorefull scale manufacturingimmune drugsimmune modulationimmune regulationimmune suppressionimmune suppressive activityimmune suppressive agentimmune suppressive functionimmune suppressorimmune-based therapeuticsimmunologic reactivity controlimmunologic therapeuticsimmunomodulatoryimmunoregulationimmunoregulatoryimmunosuppressive activityimmunosuppressive functionimmunosuppressive responseimmunosuppressive substanceimmunosuppressorimmunotherapeuticsimmunotherapy agentimprovedinfusionsinhibitorinjury to the vasculatureinnovateinnovationinnovativeinterestinterferon beta 2kidney allograftkidney txlarge scale manufacturinglarge scale productionlymph organlymphatic organlymphoid organmAbsmTORmalignancymammalian target of rapamycinmass productionmeetingmeetingsmonoclonal Absmultidisciplinarymycophenolate mofetilmycophenolic acid morpholinoethyl esternano medicinalnano medicinenano particlenano particle deliverynano technano technologynano therapynano-sized particlenano-technologicalnanocarriernanomaterialsnanomedicinalnanomedicinenanoparticlenanoparticle deliverednanoparticle deliverynanoparticle therapynanosized particlenanotechnanotechnologicalnanotherapeuticnanotherapynanovesselneoplasm/cancernon-human primatenonhuman primateorgan allograftorgan graftorgan xenograftpathology imagingpost-transplantpost-transplantationposttransplantposttransplantationreceptorrenal allograftsite targeted deliverysmall moleculesuccesstargeted deliverytherapeutic nanoparticlestissue graftingtraffickingtransplantvascular injuryvirtual
Description preview
Nanotechnology (Core C)
Summary
A major unmet medical need to improve long-term organ transplant outcomes is the development of safer and
more effective immunosuppressive regimens. One such approach is the design of innovative nanodelivery
platforms that release immune therapeutics within specific immune cell types or graft tissue sites, with…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click